Screener
TG Therapeutics TGTX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|
| Decrease in lease liabilities | (832) | (1,061) |
| Decrease in other current liabilities | (1,879) | (2,370) |
| Increase in deferred revenue | 1,310 | 1,927 |
| Net cash provided by (used in) operating activities | 21,369 | (21,279) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Proceeds from maturity of held-to-maturity securities | 29,000 | 129,750 |
| Investment in held-to-maturity securities | (37,490) | (145,359) |
| Purchases of equity investments | — | (1,250) |
Document
FAQ
- What is TG Therapeutics's operating cash flow?
- TG Therapeutics (TGTX) reported operating cash flow of $39.26M in Q2 2026.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about TG Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude